The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Jeff Sevigny,Ping Chiao,Thierry Bussière,Paul H. Weinreb,Leslie Williams,Marcel Maier,Robert Dunstan,Stephen Salloway,Tianle Chen,Yan Ling,John O’Gorman,Fang Qian,Mahin Arastu,Mingwei Li,Sowmya Chollate,Melanie S. Brennan,Omar Quintero-Monzon,Robert H. Scannevin,H. Moore Arnold,Thomas Engber,Kenneth Rhodes,James Ferrero,Yaming Hang,Alvydas Mikulskis,Jan Grimm,Christoph Hock,Roger M. Nitsch,Alfred Sandrock
DOI: https://doi.org/10.1038/nature19323
IF: 64.8
2016-08-31
Nature
Abstract:Alzheimer’s disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating—Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.
multidisciplinary sciences